ClinicalTrials.gg

Endometriosis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 921 studies for Endometriosis across more than 10 countries. 267 are recruiting or about to start. 806 of them are mainly about Endometriosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

ClinicalTrials.gov finds 964 studies for Endometriosis. How that becomes 920 here

This page counts the studies the registry files under Endometriosis, and those it files under no condition that list Endometriosisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 964Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −17List Endometriosis as a condition, but the registry did not file them under itMost often written as “Endometriosis Related Pain” (5), “Deep Endometriosis” (3), and “Endometriosis-related Pain” (2). The registry filed them under other conditions only, most often Urinary Bladder, Overactive (4) and Chronic Pain (2).
  3. −27Match it another way23 name it in the title and 4 in a keyword.
  4. 920The count on this page30 of them list Endometriosis in their own words; the registry filed them under no condition.

Status

Completed
413
Recruiting
178
Status unknown
143
Not yet recruiting
74
Terminated
36
Active, not recruiting
31

Phase

Phase 2
116
Phase 3
64
Phase 4
50
Phase 1
40
Early Phase 1
9

Where

United States
169
France
128
Italy
104
China
47
Spain
42
Turkey
38

Who develops what

Add Endometriosis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 7 companies, 7 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Changchun GeneScience Pharmaceutical, Jiangsu HengRui Medicine and Kissei Pharmaceutical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
LeuprolideRecent, limited
Evidence
  • NCT07015268 · Kissei Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Leuprorelin acetate” · registered Jun 2025
  • NCT03931915 · aska pharmaceutical co ltd · Phase 3 · comparator · “Leuprorelin acetate” · registered Apr 2019
  • NCT02778919 · Kissei Pharmaceutical Co., Ltd. · Phase 2 · comparator · “Leuprorelin acetate” · registered May 2016
  • NCT02203331 · Bayer · Phase 2 · comparator · “Lupron / Leuprolide acetate” · registered Jul 2014
  • NCT01767090 · Astellas Pharma Inc · Phase 2 · comparator · “Leuprorelin acetate” · registered Dec 2012
Takeda15% of its industry studiesUS: Tolmar Inc. (FDA 2002)EU: Accord Healthcare S.L.U. (EMA 2022)11 study
EstradiolRecent, limited
Evidence
  • NCT05894135 · Bio Genuine (Shanghai) Biotech Co., Ltd. · Phase 3 · live · background · “ABT(E2 1 mg / NETA 0.5 mg)” · registered May 2023
  • NCT04372121 · Kissei Pharmaceutical Co., Ltd. · Phase 3 · background · “Add-back capsule (E2 1 mg / NETA 0.5 mg)” · registered Apr 2020
  • NCT04335591 · Kissei Pharmaceutical Co., Ltd. · Phase 3 · background · “Add-back capsule (E2 1 mg / NETA 0.5 mg)” · registered Apr 2020
  • NCT03992846 · Kissei Pharmaceutical Co., Ltd. · Phase 3 · background · “Add-back capsule (E2 1 mg / NETA 0.5 mg)” · registered Jun 2019
  • NCT03986944 · Kissei Pharmaceutical Co., Ltd. · Phase 3 · background · “Add-back capsule (E2 1 mg / NETA 0.5 mg)” · registered Jun 2019
Novo Nordisk A/S17% of its industry studiesUS: off-patent, 37 generics marketed11 study
dienogestRecent, limited
Evidence
  • NCT06543550 · Bio Meds Pharmaceutica Ltda · Phase 4 · live · comparator · “Oral Dienogest” · registered Jul 2024
Bayer80% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
linzagolix☆ Track1 live phase-3 study: NCT07015268Kissei Pharmaceutical Co., Ltd.
HMI-115☆ Track1 live phase-3 study: NCT07318688Hope Medicine (Nanjing) Co., Ltd

The 2 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jun 2027 est.vipoglanstat · Gesynta Pharma AB · Phase 2 main aimNCT07260669 A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis — primary endpoint: Percentage of Participants who meet the Predefined NMPP Responder Criteria from Baseline to Fourth Month of Treatment · 213 enrolled
  • Nov 2027 est.linzagolix · Kissei Pharmaceutical Co., Ltd. · Phase 3 main aimvs LeuprolideNCT07015268 A Clinical Study of KLH-2109 in Patients With Endometriosis — primary endpoint: Change from baseline in the maximum NRS score for pelvic pain during 28 days prior to 12 weeks of the investigational product treatment · 288 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Endometriosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Hormonal contraceptives 1 open · Aromatase inhibitors 1 open · Statins 1 open · Local anesthetics 1 open · Progestins 5

Coming up

95studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger. 18 (10%) take children under 18. 169 (95%) are for women only and 0 (0%) for men only; 39 (22%) take healthy volunteers.

Recruiting studies that take each age, of 178
AgeWomenMen
107 (4%)2 (1%)
18167 (94%)9 (5%)
30176 (99%)8 (4%)
40168 (94%)8 (4%)
5094 (53%)7 (4%)
6558 (33%)6 (3%)
7555 (31%)6 (3%)
8554 (30%)6 (3%)

Across all 921 studies, recruiting or not: 73% stop at 75 or younger and 71% at 65; 9% take children; 95% are for women only and 1% for men only; 23% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Endometriosis studies take

Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 17 mo3–26 · 24 studies——
Phase 227 mo18–37 · 44 studies——
Phase 329 mo21–42 · 33 studies——
Interventional, no phase25 mo13–44 · 213 studies—24 mo13–44 · 198 studies
Observational30 mo14–47 · 182 studies—30 mo14–48 · 155 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 921. Browse all 921 → or search them.